XML 34 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Note 1 - Business and Organization (Details Textual)
12 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total $ (11,440,000) $ (10,696,000)    
Net Cash Provided by (Used in) Operating Activities, Total (4,422,000) (3,891,000)    
Working Capital 3,289,000      
Assets, Current, Total 1,065,000 955,000    
Revenue from Contract with Customer, Including Assessed Tax 1,861,000 1,364,000    
Cash Provided by Financing Activities 4,466,000      
Cash and Cash Equivalents, at Carrying Value, Ending Balance $ 655,000 $ 655,000 $ 990,000  
Number of Wholly-Owned Subsidiaries 4      
BioLargo Engineering, Science & Technologies, LLC [Member]        
Noncontrolling Interest, Ownership Percentage by Parent 97.50%     100.00%
Biolargo [Member] | Clyra Medical Technology Inc [Member]        
Noncontrolling Interest, Ownership Percentage by Parent 36.00%      
Convertible Notes, Maturing August 12 and 16, 2020 [Member]        
Convertible Notes Payable, Total $ 550,000